A Game Changer: Pylarify Imaging for Prostate Cancer Diagnosis & Detection
July 1, 2021
There’s a new, FDA-approved imaging that can help detect prostate cancer.
As of May 2021, Pylarify, a type of PET scan has been approved to identify suspected prostate cancer metastasis or recurrence.
About one in nine men are diagnosed with prostate cancer in their lifetime. Prostate cancer is the most common cancer in men (not including skin cancer). It is also one of the leading causes of cancer death among men. Prostate cancer develops mainly in older men and in African-American men. About six cases in ten are diagnosed in men aged 65 or older.
Prostate cancer often goes undetected as there are typically no real indicative symptoms. As prostate cancer spreads, oftentimes symptoms may develop.
Pylarify is imaging that more accurately identifies prostate cancer than traditional imaging (typically a MRI or ultrasound). It can also detect prostate cancer earlier.
Traditional imaging, especially in men with low PSA levels, in which prostate cancer may possibly be present, is not always able to identify the location and extent of cancer in many cases.
Pylarify targets a protein which is overexpressed on the surface of more than 90% of prostate cancer, both in early detection and in surveillance of metastatic prostate cancer. It does this by binding to the protein allowing for the PET scan to better detect and locate the disease.
Although waiting for approval for coverage from Medicare and Medicaid, once this imaging is covered, it will be a game changer in detection of prostate cancer.
Once approved, Austin Diagnostic Imaging (ARA), a well trusted and used imaging center throughout the Austin area will be ready to offer this novel PET/CT imaging (Pylarify) at multiple sites through the region.
This type of imaging provides immense benefits in increasing the length and quality of life for patients with prostate cancer that are treatable.
Austin Urology Institute will offer this imaging for appropriate patients as the approval for coverage is provided.
If you have any questions regarding Pylarify or theranostics at ARA please contact our Provider Relations Associates at ProviderInfo@ausrad.com or Austin Urology Institute at 512.694.888 to schedule a consultation with a provider.
Virtual Visits Available
We offer both in-clinic and remote telemedicine consultations worldwide.